Scarica l'app Stockscreener
741.45
1.07%
-7.99
Pre-mercato:
737.92
-3.53
-0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$749.44
Aprire:
$753.96
Volume 24 ore:
1.31M
Relative Volume:
1.33
Capitalizzazione di mercato:
$77.93B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
17.84
EPS:
41.5659
Flusso di cassa netto:
$3.88B
1 W Prestazione:
-1.61%
1M Prestazione:
-4.20%
6M Prestazione:
+33.70%
1 anno Prestazione:
+8.55%
Intervallo 1D:
$735.61
$774.37
Intervallo di 1 settimana:
$735.61
$776.25
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
FDA Action Alert: Sanofi/Regeneron, Merck, REGENXBIO and More - BioSpace
Regeneron Q4 Growth Highlights Expanding Pipeline And Upcoming FDA Decisions - simplywall.st
National Pension Service Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Aug Catalysts: Is Regeneron Pharmaceuticals Inc part of any ETFJuly 2025 Technicals & Consistent Growth Equity Picks - baoquankhu1.vn
Regeneron (REGN) Draws Higher Target From TD Cowen - Insider Monkey
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines - Finviz
How Regeneron Pharmaceuticals Inc. (REGN) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Regeneron (REGN) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Regeneron: Expect Double-Digit Growth In 2026 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by TD Waterhouse Canada Inc. - MarketBeat
Wall Street Zen Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold - MarketBeat
Regeneron Pharmaceuticals (REGN) Margin Slippage Tests Bullish Earnings Growth Narrative - simplywall.st
10 Most Profitable Healthcare Stocks to Buy - Insider Monkey
Regeneron’s Earnings Call: Growth Engines and Rising Costs - TipRanks
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail
This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business - The Motley Fool
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Raises Dividend to $0.94 Per Share - MarketBeat
Regeneron (REGN) Reports Strong Q4 2025 Revenue Growth - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highl - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target - TipRanks
Key facts: Regeneron gains FDA approval; Q4 revenue rises 3%; trials for weight-loss drug start - TradingView
Regeneron bets added cholesterol benefit will help its obesity drug stand out - WTVB
Regeneron beats quarterly profit estimates on Dupixent strength | Business Information & News | FE - Westlaw Today
Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Beats Expectations By $0.96 EPS - MarketBeat
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
Regeneron (REGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Regeneron Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory - Benzinga
Levels Update: Can Regeneron Pharmaceuticals Inc reach all time highs this yearWeekly Gains Summary & Technical Confirmation Alerts - baoquankhu1.vn
Regeneron (REGN) Projects 2026 Capital Expenditure of $1.3 Billi - GuruFocus
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Regeneron beats expectations on Dupixent strength despite pressure on Eylea - marketscreener.com
Sector Update: Health Care Stocks Fall Premarket Friday - marketscreener.com
Earnings Summary: Regeneron Pharmaceuticals Q4 - Benzinga
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Regeneron Earnings Report: Strategic Growth in 2025- Intellectia AI™ - Intellectia AI
A High-Dose Bet Is Paying Off For Regeneron, But Core Eylea Weakness Caps Upside - Stocktwits
Regeneron beats quarterly profit estimates on Dupixent strength - Yahoo Finance
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition - Chartmill
Regeneron: Q4 Earnings Snapshot - kare11.com
Regeneron posts Q4 beat thanks to Sanofi tie-up (REGN:NASDAQ) - Seeking Alpha
Regeneron (REGN) Surpasses Q4 Expectations with Strong Earnings - GuruFocus
Summit Global Investments Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Achieves Revenue Milestone and Expands Medicine Approvals - GuruFocus
REGENERON PHARMACEUTICALS ($REGN) Releases Q4 2025 Earnings - Quiver Quantitative
Regeneron Pharmaceuticals Q4 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - The Manila Times
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA - TradingView
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):